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Abstract 
Direct bromination of the tyrosine residues of peptides and antibodies with bromine-76, to 
create probes for PET imaging, has been reported. For peptides that do not contain tyrosine 
residues, however, a prosthetic group is required to achieve labeling via conjugation to other 
functional groups such as terminal α-amines or lysine ε-amines. The goal of this study was to 
develop new strategies for labeling small peptides with Br-76 using either a direct labeling 
method or a prosthetic group, depending on the available functional group on the peptides. A 
new  labeling  agent,  N-succinimidyl-3-[
76Br]bromo-2,6-dimethoxybenzoate  ([
76Br]SBDMB) 
was prepared for cyclic RGD peptide labeling. N-succinimidyl-2, 6-dimethoxybenzoate was 
also used to pre-attach a 2, 6-dimethoxybenzoyl (DMB) moiety to the peptide, which could 
then be labeled with Br-76. A competitive cell binding assay was performed to determine the 
binding affinity of the brominated peptides. PET imaging of U87MG human glioblastoma 
xenografted  mice  was  performed  using  [
76Br]-BrE[c(RGDyK)]2  and  [
76Br]-BrDMB-E[c 
(RGDyK)]2. An ex vivo biodistribution assay was performed to confirm PET quantification. The 
mechanisms of bromination reaction between DMB-c(RGDyK) and the brominating agent 
CH3COOBr were investigated with the SCRF-B3LYP/6-31G* method with the Gaussian 09 
program package. The yield for direct labeling of c(RGDyK) and E[c(RGDyK)]2 using chlo-
ramine-T and peracetic acid at ambient temperature was greater than 50%. The yield for 
[
76Br]SBDMB was over 60% using peracetic acid. The conjugation yields for labeling c(RGDfK) 
and c(RGDyK) were over 70% using the prosthetic group at room temperature. Labeling yield 
for pre-conjugated peptides was over 60%. SDMB conjugation and bromination did not affect 
the binding affinity of the peptides with integrin receptors. Both [
76Br]Br-E[c(RGDyK)]2 and 
[
76Br]BrDMB-E[c(RGDyK)]2 showed high tumor uptake in U87MG tumor bearing mice. The 
specificity  of  the  imaging  tracers  was  confirmed  by  decreased  tumor  uptake  after 
co-administration of unlabeled dimeric RGD peptides. The energy barrier of the transition 
state of bromination for the dimethoxybenzoyl group was about 9 kcal/mol lower than that 
for  the  tyrosine  residue.  In  conclusion,  the  newly  developed  N-succinimidyl-2, 
6-dimethoxybenzoate  molecule  can  be  used  either  for  one  step  labeling  through 
pre-conjugation or as the precursor for a Br-76 labeled prosthetic group for indirect labeling. 
Radiobromination on a dimethoxybenzoyl group has selectivity over radiobromination on 
tyrosine. The energy barrier difference of the transition states of bromination between the 
dimethoxybenzoyl group and the tyrosine residue may account for the reaction selectivity 
when both groups are present in the same molecule. 
Ivyspring  
International Publisher   Theranostics 2011, 1 
 
http://www.thno.org 
342 
Key  words:  Bromine-76,  Arg-Gly-Asp  (RGD)  peptides,  positron  emission  tomography  (PET), 
N-succinimidyl-2,6-dimethoxybenzoate 
INTRODUCTION 
Bromine-76,  a  positron  emitter  with  57%  posi-
tron  emission  and  43%  electron  capture,  has  been 
used to label antibodies and small molecules for pos-
itron  emission  tomography  (PET)  imaging.[1]  The 
relatively long half-life (16.2 h) and high positron en-
ergy (3.4 MeV maximum) also make it possible to use 
76Br for internal radiotherapy. The therapeutic effect 
can also be attributed to the electron capture compo-
nent of the Br-76 radionuclidic decay.[2] High specific 
activity 76Br can be produced with a high energy cy-
clotron (>50 MeV) using the 75As(3He, 2n)76Br nuclear 
reaction[3] or with a low energy cyclotron (~16 MeV) 
using the 76Se(p, n)76Br nuclear reaction.[4]  
The  radiochemistry  of  bromine,  analogous  to 
that of iodine, relies primarily on oxidative electro-
philic substitution to provide a relatively stable radi-
olabel. The radiobromination of small molecules typ-
ically  involves  the  oxidative  substitution  of  a  tri-
alkyltin leaving group using various oxidizing agents. 
Large molecular weight proteins, such as antibodies, 
can be labeled directly on their tyrosine residues or 
through a prosthetic group that reacts with the amines 
of  lysine  residues.  The  direct  labeling  method  in-
volves either enzymatic oxidation[5] or chemical oxi-
dizing  agents  such  as  chloramine-T.[6]  Prosthetic 
methods  using                    N-succinimidyl 
3-(4-hydroxyphenyl)  propionate,[7]  N-succinimidyl 
p-(4-tri-n-butylstannyl)benzoate[8] or N-succinimidyl 
p-(4-trimethystannyl)benzoate[9]  have  also  been  re-
ported.  
The  cyclic  Arg-Gly-Asp  (RGD)  peptides  have 
been  labeled  with  various  radioisotopes,  including 
18F, 64Cu, 89Zr, 99mTc and 111In,[10-12] for imaging αvβ3 
integrin expression in tumors. 125I has also been used 
to directly label RGD peptides using iodogen[13] or 
chloramine-T.[14] For labeling peptides that contain 
no  tyrosine  residue,  such  as  c(RGDfK),  labeled 
N-succinimidyl  4-[76Br]-bromobenzoate  (SBB)  has 
been  used  with  satisfactory  results.  However,  the 
drawback  of  this  indirect  method  is  that  it  usually 
requires  two  HPLC  purifications,  one  for  purifying 
SBB and the other for purifying the peptide conjugate. 
Alternatively, direct labeling may be achieved by first 
attaching a prosthetic group to the peptides.  
We  have  previously  labeled  small  molecules 
with  76Br  and  observed  that  an  electron  rich  2, 
6-dimethoxybenzene moiety can easily attach a bro-
mine  to  its  3  position  ortho  to  the  methoxy  group 
without  the  need  of  a  trialkyltin  leaving  group.[15] 
Based  on  this  dimethoxybenzene  structure,  we  de-
veloped  a  new  labeling  agent,  N-succinimidyl- 
2,6-dimethoxybenzoate that can be used either for one 
step labeling through pre-conjugation or as the pre-
cursor for a 76Br-labeled prosthetic group for indirect 
labeling. Moreover, we investigated the mechanism of 
bromination  reaction  with  the  SCRF-B3LYP/6-31G* 
method. 
MATERIALS AND METHODS 
General materials 
Cyclic RGD peptides were purchased from Pep-
tides  International  (Louisville,  KY),  and  all  other 
chemicals  were  purchased  from  Sigma-Aldrich  (St. 
Louis,  MO).  The  chemical  structures  of  cyclic  RGD 
peptides c(RGDfK), c(RGDyK) and their glutamic acid 
linked dimeric forms E[c(RGDfK)]2 and E[c(RGDyK)]2 
are  shown  in  Figure  1A.  1H  and  13C  NMR  spectra 
were  recorded  at  300  MHz  on  a  Bruker  300  Ul-
tra-Shield  spectrometer  in  CDCl3  with  tetra-
methylsilane  (TMS)  as  the  internal  standard.  Mass 
spectra (MS) were obtained using a Thermo-Finnigan 
Trace DSQ GC-MS or Waters Acquity UPLC system 
coupled  with  a  Waters  Qtof  Premier  MS  (LC-MS). 
Preparative reversed-phase HPLC was performed on 
a Waters 600 gradient system with a Waters 996 PDA 
detector using a Higgins PROTO 300 C18 column (5 
µm, 250 x 20 mm). Analytical reversed-phase HPLC 
was  performed  on  a  separate  Waters  600  gradient 
system also with a 996 PDA detector, plus a Beckman 
170 radioisotope detector using a Vydac protein and 
peptide column (5 µm, 250 x 4.6 mm). The flow rate 
was  10  mL/min  for  the  preparative  column  and  1 
mL/min for the analytical column running the same 
linear gradient starting from 5% A (0.1% TFA in ace-
tonitrile)  and  95% B  (0.1%  in  water)  for 5  min  and 
increasing A to 65% at 35 min. A Varian BOND ELUT 
C18 column (50 mg) was used for solid phase extrac-
tion of labeled peptides. 
Preparation of N-succinimidyl 2, 6-dimethoxy-
benzoate (SDMB)  
1.0  g  of  1,  3-dicyclohexylcarbodiimide  (DCC) 
was  added  to  a  mixture  of  0.9  g  of  2, 
6-dimethoxybenzoic  acid  and  0.58  g  of 
N-hydroxysuccinimide in 20 mL of methylene chlo-
ride (CH2Cl2), and the reaction mixture was stirred at 
room temperature overnight. The precipitate was fil-Theranostics 2011, 1 
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tered  and  the  product  was  purified  with  silica  gel 
column flash chromatography with 30% ethyl acetate. 
The fractions containing the desired product (based 
on TLC and GC-MS analysis) were combined, and the 
solvent was evaporated with reduced pressure to give 
0.7 g of product (51% yield) with a 99% purity based 
on GC-MS analysis (Rt = 7.7 min). 1H NMR (CDCl3) δ 
2.88 (s, 4H), 3.89 (s, 6H), 6.69 (d, 2H), 7.39 (t, 1H). 13C 
NMR (CDCl3) δ 25.7, 56.4, 104.0, 106.9, 133,4, 159.0, 
161.5,  169.0.  GC-MS  (EI)  280  (M+),  193,  165  (calc: 
279.1).  
 
 
Figure  1.  (A)  Chemical  structures  of  RGD  peptides.  (B)  Synthesis  of  brominated  RGD  peptide  standards  and 
pre-conjugated RGD peptides.  
 
 
Preparation of N-succinimidyl 3-bromo-2, 
6-dimethoxybenzoate (SBDMB) 
The  3-bromo-2,  6-dimethoxybenzoic  acid  was 
prepared in a 100 mL round bottom flask containing 
2.0 g of 2, 6-dimethoxybenzoic acid in 20 mL acetoni-
trile  by  adding  0.9  g  of  bromine.  The  reaction  was 
monitored with GC-MS. After 30 min, all the starting 
material was converted to the desired product. The 
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solvent was removed with a rotary evaporation ap-
paratus to give 2.7 g of product with a 95% yield and 
96% purity based on GC-MS analysis (Rt = 6.2 min), 
and the solid product was used without further puri-
fication. 1H NMR (CDCl3) δ 3.88 (s, 3H), 3.96 (s, 3H), 
6.66 (d, 1H), 7.56 (d, 1H). GC-MS (EI) 260, 262 (M+), 
214, 185, 157 (calc: 260.0).  
The following were added to a 50 mL flask: 0.68 
g  of  3-bromo-2,6-dimethoxybenzoic  acid,  0.33  g  of 
N-hydroxysuccimide,  0.59  g  of  DCC  and  20  mL  of 
CH2Cl2. The mixture was stirred at room temperature 
overnight. At the end of the reaction, the solid was 
removed  by  filtration  and  the  filtrate  was  passed 
through a small silica gel column. Upon standing at 
room temperature overnight, the solvent was evapo-
rated to give 0.5 g of pale yellow solid (54% yield), 
and the product was checked with GC-MS and used 
without  further  purification.  The  GC-MS  analysis 
showed that the product had over 95% purity with a 
8.3 min retention time. 1H NMR (CDCl3) δ 2.90 (s, 4H), 
3.89 (s, 3H), 3.99 (s, 3H), 6.67 (d, 1H), 7.63 (d, 1H). 13C 
NMR  (CDCl3)  δ  25.7,  56.7,  62.7,  107.9,  108.5,  114.0, 
136,7, 156.2, 158.0, 160.5, 168.8. GC-MS (EI) 357, 359 
(M+), 227, 184, 156 (calc: 356.9). 
Preparation of Bromo(Tyr)-c(RGDyK) 
2  µL  of  acetic  acid  and  1 µL  of  bromine  were 
added  to  a  4  mL  glass  vial  containing  10.4  mg  of 
c(RGDyK) in 0.3 mL of water.. After 30 min, the reac-
tion was quenched with 10 mg of sodium metabisul-
fite in 100 µL of water and injected onto a preparative 
RP HPLC. The product was collected (Rt = 17.1 min) 
and lyophilized to give 4.5 mg of product (yield 35%). 
Bromo(Tyr)-c(RGDyK) was denoted as Brt-c(RGDyK). 
LC-MS: [MH]+ = 698.2899 (m/z), calc: 698.2261. 
Preparation of Bromo(Tyr)-2, 
6-dimethoxybenzoyl-c(RGDyK) 
0.5 mg of SDMB in 0.1 mL of acetonitrile was 
added  to  a  4  mL  glass  vial  containing  1.5  mg  of 
Br-c(RGDyK) in 0.1 mL  of 0.1 M borate buffer (pH 
8.4), and the mixture was reacted at 4 C overnight. 
The reaction was quenched with 10 µL of acetic acid 
and purified with preparative HPLC to give 0.9 mg of 
product  (50%  yield,  Rt  =  22.5  min).  Bromo(Tyr)-2, 
6-dimethoxybenzoyl-c(RGDyK)  was  denoted  as 
BrtDMB-c(RGDyK). LC-MS: [MH]+= 862.2984 (m/z), 
calc: 862.2735. 
Synthesis of 2, 6-dimethoxybenzoyl-c(RGDfK), 2, 
6-dimethoxybenzoyl-c(RGDyK), 2, 
6-dimethoxybenzoyl-E[c(RGDfK)]2 and 2, 
6-dimethoxybenzoyl-E[c(RGDyK)]2 
20 µL of diisopropylethylamine (DIPEA) and 5 
mg of N-succinimidyl 2, 6-dimethoxybenzoate in 100 
µL of DMF were added to a 4 mL glass vial containing 
14.0 mg of c(RGDfK) in 100 µL of DMF, and the mix-
ture  was  stirred  at  room  temperature  for  1  hr.  The 
reaction was quenched with 25 µL of acetic acid and 
the reaction mixture was diluted with 0.5 mL of water 
and injected onto a preparative RP HPLC for purifi-
cation. The peak containing desired product was col-
lected (Rt = 22.8 min) and the solution was frozen over 
dry-ice and lyophilized overnight to give 11.8 mg of 
product  denoted  as  DMB-c(RGDfK),  (66%  yield). 
LC-MS: [MH]+ = 768.4506 (m/z), calc: 768.3681. 
2, 6-Dimethoxybenzoyl-c(RGDyK), 2,6-dimetho-
xybenzoyl-E[c(RGDfK)]2  and  2,6-dimetho-
xybenzoyl-E[c(RGDyK)]2 were prepared in a similar 
manner  and  were  denoted  as  DMB-c(RGDyK), 
DMB-E[c(RGDfK)]2, and DMB-E[c(RGDyK)]2, respec-
tively.  DMB-c(RGDyK)  (yield  63%,  Rt  =  20.2  min), 
LC-MS:  [MH]+  =  784.2714  (m/z),  calc:  784.3630; 
DMB-E[c(RGDfK)]2 (yield 39%, Rt = 23.2 min), LC-MS: 
[MH]+  =  1482.7344  (m/z),  calc:  1482.7130; 
DMB-E[c(RGDyK)]2  (yield  49%,  Rt  =  19.9  min), 
LC-MS: [MH]+=1514.5557 (m/z), calc: 1514.7028. 
Synthesis of 3-bromo-2, 
6-dimethoxybenzoyl-c(RGDfK), 3-bromo-2, 
6-dimethoxybenzoyl-c(RGDyK), 3-bromo-2, 
6-dimethoxybenzoyl-E[c(RGDfK)]2 and 
3-bromo-2, 6-dimethoxybenzoyl-E[c(RGDyK)]2 
N-succinimidyl  3-bromo-2,  6-dimethoxy-
benzoate (41 mg) was dissolved in 200 µL of acetoni-
trile and 50 µL of this solution was added to each of 4 
separate  vials  containing  variously  11.0  mg  of 
c(RGDfK),  12.5  mg  of  c(RGDyK),  24.0  mg  of 
E[c(RGDfK)]2 or 20.0 mg of E[c(RGDyK)]2. Each vial 
also contained 200 µL of DMF and 20 µL of DIPEA. 
After two hours, 25 µL of acetic acid and 0.5 mL of 
water were added to each vial. Each sample was pu-
rified with preparative RP HPLC and lyophilized to 
give  the  desired  product.  3-Bromo-2, 
6-dimethoxybenzoyl-c(RGDfK),  3-bromo-2, 
6-dimethoxybenzoyl-c(RGDyK),  3-bromo-2, 
6-dimethoxybenzoyl-E[c(RGDfK)]2  and  3-bromo-2, 
6-dimethoxybenzoyl-E[c(RGDyK)]2  were  denoted  as 
BrDMB-c(RGDfK),  BrDMB-c(RGDyK), 
BrDMB-E[c(RGDfK)]2,  and  BrDMB-E[c(RGDyK)]2, 
respectively. BrDMB-c(RGDfK), (yield 33%, Rt = 25.0 
min), LC-MS: [MH]+ = 846.3982 (m/z), calc: 846.2786; 
BrDMB-c(RGDyK),  (yield  22%,  22.8  min),  LC-MS: 
[MH]+  =  862.4221  (m/z),  calc:  862.2735; 
BrDMB-E[c(RGDfK)]2  (yield  21%,  Rt  =  25.4  min), 
LC-MS:  [MH]+  =  1560.8088  (m/z),  calc:1560.6235; 
BrDMB-E[c(RGDyK)]2  (yield  14%,  Rt  =  22.1  min), 
LC-MS: [MH]+=1592.8000 (m/z), calc: 1592.6133. Theranostics 2011, 1 
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Radiochemistry 
Bromine-76 was produced by cyclotron irradia-
tion of high-purity arsenic targets through a 75As(3He, 
2n)76Br nuclear reaction and isolated by chromic acid 
dissolution and oxidation followed by simple distilla-
tion of [76Br]HBr. The radiobromine was trapped in an 
aqueous solution of NH4OH. The solution was evap-
orated to produce dry [76Br]NH4Br.  
Direct labeling of peptides with chloramine-T  
5-10 µL of [76Br]NH4Br in water was added to 
about 100 µg of either c(RGDyK) or E[c(RGDyK)]2 in 
0.1 mL of pH 6.8 acetate buffer in a 1 mL polypro-
pylene tube, and followed by adding 100 µg of chlor-
amine-T in 10 µL of water. After 10 min, the reaction 
mixture was quenched by adding 200 µg of sodium 
metabisulfite in 10 µL of water and then injected onto 
an analytical RP HPLC column. Radioactivity peaks 
were collected and measured using a dose calibrator. 
Most reactions were performed at room temperature 
and a few selected reactions were performed at 80 °C 
to test the temperature effect.  
Direct labeling of peptides with peracetic acid 
5-10 µL of [76Br]NH4Br (~0.5-1.0 mCi) in water 
was  added  to  about  100  µg  of  c(RGDyK)  or 
E[c(RGDyK)]2 in 0.1 mL of water in a 1 mL polypro-
pylene tube, followed by adding either 2 µL or 0.2 µL 
of  anhydrous  peracetic  acid  as  the  oxidizing  agent. 
After 10 min, the reaction mixture was injected onto 
an analytical RP HPLC column. Radioactivity peaks 
were collected and measured using a dose calibrator. 
The reactions were performed at room temperature 
when 2 µL of peracetic acid was used, and reactions 
were performed at room temperature and 80 °C when 
0.2 µL of peracetic acid was used.  
Preparing Br-76 labeled prosthetic group 
[
76Br]SBDMB 
About 100 µg of SDMB in 50 µL of acetonitroile 
was added to a 1 mL polypropylene tube, followed by 
adding 5-10 µL of [76Br]NH4Br (~0.5-1.0 mCi) and 100 
µg of chloramine-T in 10 µL of water or 2 µL anhy-
drous peracetic acid. The mixture was heated at 80 °C 
for 10 min and injected onto a Waters Symmetry C18 
column  (5  µm,  3.9  x  150  mm)  using  40%  acetoni-
trile/water  as  the  mobile  phase  containing  0.1%  of 
acetic acid with a 1 mL/min flow rate. The radioactive 
product was collected and trapped on a Waters C18 
Sep-Pak column. The radioactivity on the C18 column 
was eluted with 1 mL of CH2Cl2 to a 1 mL polypro-
pylene tube, the small amount of water on top of the 
organic phase was removed by a needle syringe, and 
CH2Cl2 was removed by argon flow. The radioactivity 
was redissolved in 5 µL of acetonitrile for further use. 
Labeling RGD peptides with Br-76 labeled pros-
thetic group 
About 300 to 500 µg of RGD peptide in 100 µL of 
1 M borate buffer (pH 8.4) was  added to the 1 mL 
polypropylene tube containing Br-76 radioactivity as 
described above. The mixture was vortexed and al-
lowed to react at room temperature for 10 min and 
then was loaded onto the RP HPLC for purification. 
The radioactive peak was collected, diluted with 10 
mL water and then trapped on a Varian Bond-Elute 
C18 column. The column was washed with 5 mL of 
water and the radioactivity eluted with 200 µL of 10 
mM HCl ethanol solution. The ethanol was removed 
using  argon  flow  and  radioactivity  re-dissolved  in 
saline for further use. 
Br-76 labeling of pre-conjugated RGD peptides 
5-10 µL of [76Br]NH4Br in water was added to 
about 100 µg of pre-conjugated RGD peptide in 100 
µL of water in a 1 mL polypropylene tube, followed 
by adding 0.2 µL of 32% peracetic acid in 10 µL of 
acetonitrile. The mixture was vortexed and heated at 
80  °C  for  10  min.  The  reactions  were  performed  at 
room temperature when 2 µL of peracetic acid was 
used  (see  section  on  preparing  Br-76  labeled  pros-
thetic group [76Br]SBDMB, above). The product was 
purified  with  a  procedure  similar  to  that  described 
above for the indirect labeling procedure. 
Cell binding assay 
In vitro integrin binding affinity and specificity of 
RGD peptide derivatives were assessed via a compet-
itive  cell-binding  assay  using  125I-echistatin  (Per-
kin-Elmer, Waltham, MA) as the integrin αvβ3 specific 
radioligand. Experiments were performed on human 
glioblastoma  U87MG  cells  with  high  integrin  αvβ3 
expression.[16] In brief, U87MG cells were trypsinized 
and resuspended in binding buffer containing 20 mM 
Tris  (pH  7.4),  150  mM  NaCl,  2  mM  CaCl2,  1  mM 
MgCl2, 1  mM  MnCl2 and 0.1%  BSA.  Incubation  was 
conducted with 96 well MultiScreen filter plates (Mil-
lipore, MA). For each well, the reaction volume was 
200  µL  containing  105  cells,  20  nCi  (0.78  KBq)  of 
125I-echistatin, and 0-20,000 nM of RGD compounds. 
The reaction was incubated for 60 min on a shaker at 
room temperature. After incubation, the filters were 
washed  three  times  with  the  binding  buffer.  Filter 
bound  radioactivity  was  measured  using  a  gamma 
counter  (1480  Wizard  3,  Perkin–Elmer).  Binding  re-
sults were expressed as percent of total counts, and 
IC50  values  were  calculated  using  Prism  software 
(GraphPad, La Jolla, CA). Theranostics 2011, 1 
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Animal model and PET imaging 
All animal studies were conducted in accordance 
with  the  principles  and  procedures  outlined  in  the 
NIH Guide for the Care and Use of Laboratory Ani-
mals and were approved by the Institutional Animal 
Care and Use Committee of the Clinical Center, NIH. 
The human glioblastoma cell line U87MG was grown 
in DMEM medium supplemented with 10% fetal bo-
vine  serum  (FBS),  100  IU/mL  penicillin,  and  100 
μg/mL streptomycin (Invitrogen), and in a humidi-
fied atmosphere containing 5% CO2 at 37°C. The cells 
were harvested by trypsinization with trypsin/EDTA. 
The  U87MG  tumor  model  was  developed  in  5  to 
6-week  old  female  athymic  nude  mice  (Harlan  La-
boratories)  by  injection  of  5×106  cells  into  the  right 
shoulders. Tumor growth was monitored using cali-
per measurements of perpendicular axes of the tumor. 
The mice underwent small-animal PET studies when 
the tumor volume reached 100–300 mm3 (3 - 4 weeks 
after inoculation). 
PET scans and image analysis were performed 
using an Inveon microPET scanner (Siemens Medical 
Solutions).  About  3.7  MBq  (100  μCi)  of  76Br-labeled 
RGD peptide was administered via tail vein injection 
under  isoflurane  anesthesia.  For  a  blocking  study, 
about  300  µg  of  unlabeled  dimeric  RGD  peptide 
E[c(RGDyK)]2  was  injected  30  min  before  the 
76Br-labeled  tracer.  Five-minute  static  PET  images 
were acquired at 30 min, 1 h and 2 h postinjection (n = 
3 per group). The images were reconstructed using a 
two-dimensional  ordered-subset  expectation  maxi-
mum (2D OSEM) algorithm, and no correction was 
applied for attenuation or scatter. For each scan, re-
gions  of  interest  (ROIs)  were  drawn  using  vendor 
software  (ASI  Pro  5.2.4.0)  on  decay-corrected 
whole-body  coronal  images.  The  radioactivity  con-
centrations (accumulation) within the tumor, muscle, 
liver,  and  kidneys  were  obtained  from  mean  pixel 
values  within  the  multiple  ROI  volume  and  then 
converted  to  MBq  per  milliliter.  These  values  were 
then divided by the administered activity to obtain 
(assuming  a  tissue  density  of  1  g/mL)  an  im-
age-ROI-derived  percent  injected  dose  per  gram 
(%ID/g).  
Biodistribution assay 
Immediately  after  PET  imaging,  the  tu-
mor-bearing  mice  were  sacrificed  and  dissected. 
Blood,  tumor,  major  organs,  and  tissues  were  col-
lected and wet-weighed. The radioactivity in the wet 
whole tissue was measured with a γ-counter (Pack-
ard). The results were expressed as percentage of in-
jected dose per gram of tissue (%ID/g). Values were 
expressed as mean ± SD (n = 3 per group).  
Theoretical Calculation 
All calculations included in this work were per-
formed  with  the  Gaussian  09  program  package.[17] 
CH3COOBr  molecule  was  used  as  the  brominating 
agent  for  the  no-carrier-added  electrophilic  radio-
bromination  reaction.  SCRF-B3LYP/6-31G*  calcula-
tions were carried out for bromination reactions be-
tween  DMB-c(RGDyK)  peptide  and  CH3COOBr, 
where  SCRF  calculations  were  performed  with  the 
default  PCM  model  within  G09  program[18]  with 
water  (dielectric  constant  ε  =  78.39)  as  solvent  at  a 
temperature of 298 K. The geometric parameters of 
the reactant, transition states and products have been 
optimized  and  characterized  with  SCRF-B3LYP/ 
6-31G* method. The relative energies of all stationary 
points were corrected with zero-point vibrational en-
ergies to account for the thermal effect.  
Statistical Analysis 
Quantitative data were expressed as mean ± SD. 
Means  were  compared  using  one-way  analysis  of 
variance and Student’s t test. P values of < 0.05 were 
considered statistically significant. 
 
RESULTS  
Pre-conjugation and bromination 
The  syntheses  of  brominated  RGD  peptide 
standards and pre-conjugated precursors are shown 
in Figure 1B using c(RGDyK) as an example. For di-
meric peptides, the coupling was on the -amine of 
the glutamic acid used for linking the two monomers. 
A  similar  procedure  was  followed  for  all  coupling 
reactions and the yields were generally higher for the 
monomeric RGD peptides than the dimeric counter-
parts, which can be explained by that fact that -amine 
on lysine is more reactive than the -amine on glu-
tamic acid. 
In  order  to  confirm  that  pre-conjugation  and 
bromination do not affect the binding affinity of the 
peptides to integrin receptors, we performed compet-
itive cell binding assays with 125I-echistatin as the ra-
dioligand in integrin αvβ3 positive U87MG cells. Re-
sults of the cell-binding assays were plotted and fitted 
to  sigmoid  curves  for  the  displacement  of 
125I-echistatin from U87MG cells (Figure 2A). The IC50 
values  are  listed  in  Figure  2B.  Consistent  with  the 
data  reported  previously,[19]  the  dimers  showed 
similar  binding  affinity  with  FPPRGD2  and  higher 
binding affinity than the monomers. The results in-
dicated that the preconjugation and bromination had 
little effect on the binding affinity of the peptides. 
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Figure  2.  (A)  Cell  binding  assay  of  RGD  peptides  in 
U87MG cells; (B) IC50 of each RGD compound (n = 3). 
 
 
Br-76 labeling of RGD peptides 
The radiolabeling schemes are shown in Figure 
3. The yields for direct radiobromination of c(RGDyK) 
and E[c(RDGyK)]2 using chloramine-T were over 50% 
at room temperature with minor radioactive impuri-
ties. At 80 °C, the desired products were diminished 
and  undesired  multiple  radioactive  peaks  were 
formed. When peracetic acid was used as the oxidiz-
ing agent, the labeling yields were also over 50% at 
room  temperature  with  less  radioactive  impurity. 
When diluted peracetic acid (10% of normal concen-
tration)  was  used,  the  radiochemical  yield  was  less 
than 5% even at 80 °C. However, at 80 °C the yield for 
Br-76 SBDMB and pre-conjugated RGD peptides was 
over 60% using the diluted peracetic acid. High la-
beling yields were also achieved using more concen-
trated  peracetic  acid  at  room  temperature  for  these 
reactions.  The  coupling  yields  of  [76Br]SBDMB  with 
c(RGDfK) and c(RGDyK) were over 70% and coupling 
yield  with  their  dimeric  forms  were  less  than  10% 
under similar conditions. The specific activity at the 
end of synthesis (EOS) for 
[76Br]BrDMB-E[c(RGDyK)
]2 used for imaging stud-
ies  was 262  mCi/µmol. 
We  assumed  the  specific 
activity 
for [76Br]Br-E[c(RDGyK)]2 
was  in  the  same  range 
from  the  same  batch  of 
Br-76. 
 
Figure 3. (A) Radiolabeling 
with Br-76 prosthetic group; 
(B)  Direct  labeling  vs.  la-
beling  on  pre-conjugated 
prosthetic group. 
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MicroPET imaging 
After  pre-conjugation  and  bromination,  we 
conducted  in vivo  imaging  of  [76Br]Br-E[c(RDGyK)]2 
and  [76Br]BrDMB-E[c(RGDyK)]2  in  a  U87MG  xeno-
graft mouse model. Representative coronal microPET 
images  of  U87MG  tumor  bearing  mice  at  different 
times after intravenous injection of 3.7 MBq (100 μCi) 
of the imaging tracers are shown in Figure 4A-C. The 
U87MG tumors are clearly visible with high contrast 
in relation to the contralateral background. The tumor 
uptake of [76Br]Br-E[c(RDGyK)]2 was 2.94 ± 0.55, 2.86 
± 0.52 and 2.23 ± 0.19 %ID/g at 30, 60 and 120 min p.i., 
respectively  (Fig.  4D).  The  tumor  uptake  of 
[76Br]BrDMB-E[c(RGDyK)]2 was 3.07 ± 0.73, 2.50 ± 0.62 
and 2.05 ± 0.41 %ID/g at 30, 60 and 120 min p.i., re-
spectively  (Fig.  4E).  The  receptor  specificity  of  the 
tracer accumulation was confirmed by a blocking as-
say, in which about 300 µg of unlabeled dimeric RGD 
peptide was injected 30 min before the tracer injection. 
As  shown  in  Figure  4C&F,  the  tumor  uptake  of 
[76Br]BrDMB-E[c(RGDyK)]2 was significantly lower (p 
< 0.01) than that of unblocked tumors (1.04 ± 0.22 vs. 
2.94 ± 0.55 %ID/g at 30 min, 0.62 ± 0.25 vs. 2.86 ± 0.52 
%ID/g at 60 min, and 0.38 ± 0.30 vs. 2.23 ± 0.19 %ID/g 
at  120  min).  Prominent  uptake  of 
[76Br]BrDMB-E[c(RGDyK)]2 was also observed in the 
kidneys, suggesting that this tracer is mainly excreted 
through the renal-urinary routes as is common with 
this class of integrin binding peptides.  
 
 
 
Figure 4. In vivo PET imaging of U87MG xenograft mice by 
76Br-labeled RGD peptides. Decay-corrected whole-body 
coronal microPET images of U87MG tumor–bearing mice at 30, 60, and 120 min after injection of 3.7 MBq (100 μCi) of 
[
76Br]Br-E[c(RGDyK)]2  (A)  and  [
76Br]BrDMB-E[c(RGDyK)]2  (B).  (C)  Decay-corrected  whole-body  coronal  microPET 
images  of  U87MG  tumor–bearing  mice  at  30,  60  and  120  min  after  injection  of  3.7  MBq  (100  μCi)  of  [
76Br] 
BrDMB-E[c(RGDyK)]2 with 300 µg of unlabled RGD peptide as blocking agents. (D,  E  &  F) Quantification of [
76Br] 
Br-E[c(RGDyK)]2 (D), [
76Br]BrDMB-E[c(RGDyK)]2 (E) and [
76Br]BrDMB-E[c(RGDyK)]2 (Blocking, F) in U87MG tumor, 
liver, kidneys and muscle. ROIs are shown as mean %ID/g ± SD.  
 
 
8 %ID/g
0 %ID/g
8 %ID/g
0 %ID/g
5 %ID/g
0 %ID/g
A
F
D
E
C
BTheranostics 2011, 1 
 
http://www.thno.org 
349 
 
 
Figure 5. Ex vivo biodistribution of [
76Br]BrDMB-E[c(RGDyK)]2 (3.7 MBq per mouse) in U87MG tumor bearing nude mice 
at 2 h time points after microPET scans with or without unlabeled RGD peptide as blocking agent. Columns, mean %ID/g (n 
= 3 per group); bars, SD.  
 
 
Biodistribution Studies 
In  order  to  further  confirm  the  PET  imaging 
quantification,  the  biodistribution  of 
[76Br]BrDMB-E[c(RGDyK)]2 was evaluated in U87MG 
tumor-bearing athymic nude mice immediately after 
PET imaging (Fig.  5). Consistent with PET imaging 
data,  the  tumor  uptake  measured  by  direct  tissue 
sampling and gamma-counting was 1.76 ± 0.61 %ID/g 
at the 2 h time point. The tracer accumulations in the 
kidneys  and  liver  were  2.69  ±  0.17  and  0.64  ±  0.13 
%ID/g,  respectively,  at  2  h  p.i.  In  the  blocking  ex-
periment,  U87MG  tumor  showed  significantly  de-
creased  accumulation  of  [76Br]BrDMB-E[c(RGDyK)]2 
with an uptake value of 0.53 ± 0.15 %ID/g (p < 0.001). 
 
Reaction Mechanism Study 
Grovenstein  et  al.[20]  proposed  an  iodination 
mechanism  of  phenol  with  acetyl  hypoiodite  as  an 
iodinating  agent  at  very  low  iodine  concentration. 
Acetyl hypoiodite could in principle both donate I+ 
and remove H+ in a single transition state. Based on 
the  Br-76  radiolabeling  condition,  we  used 
CH3COOBr  as  the  effective  brominating  agent.  The 
four carbon atoms of DMB-c(RGDyK) peptide labeled 
by * could be attacked by Br of CH3COOBr, respec-
tively.  The  proposed  brominating  process  included 
the attack of Br on C1* and the leaving of H2 from the 
aromatic ring of DMB-c(RGDyK) peptide. When the 
brominating  reaction  took  place  on  the  dimethox-
ybenzoyl group, the transition  state was defined as 
TS1a  and  TS1a’.  On  the  other  hand,  when  the  bro-
minating reaction took place on the tyrosine residue, 
the transition state was defined as TS1b and TS1b’. 
The main atomic numbering systems and geometric 
parameters  of  the  possible  stationary  points  are 
shown in Figure 6, and the full geometric parameters 
and the frequencies of stationary points optimized are 
listed  in  Supplementary  Material:  Table  S1-S4  in 
supporting information. The normal mode of vibra-
tion of the imaginary frequency of TS1a is given in 
Figure 7, from which one can see that the imaginary 
vibration mode in transition state is connected to the 
reactants  and  the  products.  Moreover,  the  sum  of 
Mulliken atomic charges of CH3COO group is -0.825, 
while the other part of the TS1a is +0.825, indicating 
that  the  transition  state  looks  like  δ+δ-  form,  a 
-type complex. 
As to the potential energy surface for the  bro-
minating process, the energy of TS1a, TS1a’, TS1b and 
TS1b’ are 12.7, 13.3, 21.8 and 22.1 kcal/mol (with ZPE 
correction), respectively, above the sum of the ener-
gies for the reactants. The significant difference in the 
energy barriers of TS1a and TS1b may account for the 
difference  in  the  bromination  reactivity  of  the  di-
methoxybenzoyl  group  and  the  tyrosine  residue  of 
DMB-c(RGDyK) peptide. 
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Figure 6. The possible brominating reaction channels for DMB-c(RGDyK) peptide, along with the main geometric pa-
rameters for transition states optimized with SCRF-B3LYP/6-31G*.  
 
Figure 7. The normal mode (in arrows) of imaginary vibration and group charge (e) in TS1a. 
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DISCUSSION 
Integrins  are  a  family  of  heterodimeric  glyco-
proteins responsible for the regulation of cellular ac-
tivation,  migration,  proliferation,  survival,  and  dif-
ferentiation.[21-22] One of the most important mem-
bers  of  this  receptor  class  is  integrin  αvβ3  which  is 
preferentially  expressed  on  several  types  of  cancer 
cells, including melanoma, glioma, and ovarian and 
breast cancers.[23] Integrin αvβ3 is also expressed on 
proliferating  endothelial  cells  associated  with  neo-
vascularization in both malignant tumors and normal 
tissue, but not in quiescent blood vessels.[24-25] Be-
cause arginine-glycine-aspartic acid (RGD) containing 
peptides  can  bind  strongly  to  integrin  αvβ3,  many 
RGD peptide probes have been developed for multi-
modal  imaging  of  integrin  expression.[13,  26-32]  In 
this  study,  we  chose  RGD  peptides  as  model  com-
pounds  to  test  the  novel  bromine  labeling  strategy, 
which  potentially  can  be  applied  to  bromination  of 
other proteins and peptides. Our preliminary results 
of using chloramine-T as the oxidizing agent indicat-
ed that direct labeling of RGD peptides with  76Br is 
possible,  but  the  applications  are  limited  to  stable 
peptides  containing  tyrosine  residues  such  as 
c(RGDyK)  and  E[c(RGDyK)]2.  Peptides  such  as 
c(RGDfK)  and  E[c(RGDfK)]2  contain  phenylalanine 
residues instead of tyrosine residues, thus makes di-
rect labeling impossible. In order to solve this prob-
lem,  we  introduced  N-succinimidyl  2, 
6-dimethoxybenzoate as either a prosthetic group for 
indirect labeling or a preconjugated moiety on pep-
tides for direct labeling. 
Based on the iodination mechanism proposed by 
Grovenstein et al.,[20] we conducted theoretical cal-
culations of the transition state energies for the four 
reactive sites on DMB-c(RGDyK) peptide using acetyl 
hypobromite as the brominating agent. The energy of 
the transition state for bromination on the dimethox-
ybenzoyl group (TS1a) and that on tyrosine (TS1b) are 
about  13  kcal/mol  and  22  kcal/mol,  respectively, 
above the sum of the energies for the reactants. The 
energy of TS1a is about 9 kcal/mol lower than that of 
TS1b, from which one can conclude that acetyl hypo-
bromite  could  selectively  brominate  the  dimethox-
ybenzoyl in the presence of a tyrosine residue. The 
above calculation results are in good agreement with 
the  experimental  selectivity  of  second  reaction  in 
Figure 3B. The reaction rate and selectivity seem to be 
determined by the obtained transition state (TS1a and 
TS1b).  If  the  concentration  of  peracetic  acid  is  rela-
tively high, the formation of acetyl hypobromite will 
become more rapid. That is why the reaction can oc-
cur at room temperature in the presence of 2  L of 
peracetic acid, whereas heating to 80 C is required 
when only 0.2 L of peracetic acid was used. 
Both chloramine-T and peracetic acid have been 
used  as  the  oxidizing  agents  for  halogenation  reac-
tion.[33] We found out that peracetic acid was a better 
oxidizing agent than chloramine-T for bromination of 
RGD peptides. For direct labeling of c(RGDyK), both 
chloramine-T  and  peracetic  acid  gave  satisfactory 
results. However, fewer undesired radioactive peaks 
were  formed  using  peracetic  acid.  When  peracetic 
acid was used, very few side products were formed 
even at elevated temperature, suggesting that it is a 
milder oxidizing agent than chloramine-T. The radi-
oactive brominating species was [76Br]bromine chlo-
ride when chloramine-T was used. On the other hand, 
[76Br]acetyl hypobromite was the brominating species 
when  peracetic  acid  was  used.  When  choramine-T 
was used, a large excess of N-chloro species was also 
present and would compete with [76Br] bromide chlo-
rine to consume the substrate. This could explain the 
existence  of  multiple  radioactive  peaks  due  to  the 
chlorination of the substrate on other positions of the 
substrate. This was also evident when chloramine-T 
was used to prepare 3-bromo-2, 6-dimethoxybenzoic 
acid. When equal molar amount of ammonium bro-
mide was used, little desired product was detected on 
GC-MS, and the main product was 3-chloro-2, 6 di-
methoxybenzoic acid. We also detected the formation 
of  chlorinated  c(RGDyK)  by  LC-MS  when  chlora-
mine-T was used for direct labeling.  
[76Br]Acetyl hypobromite appears to be less re-
active  towards  the  tyrosine  residue  than  the  di-
methoxybenzoyl group, as confirmed by both the ex-
perimental  data  and  theoretical  calculations.  While 
being  less  reactive  towards  hydroxyphenyl  and  al-
most  not  reactive  towards  the  4-methoxybenzoyl 
group, [76Br]acetyl hypobromite could easily bromin-
ate the dimethoxybenzoyl moiety. For example, when 
labeling pre-conjugated DMB-c(RGDyK), two radio-
active peaks were formed with HPLC retention times 
of 18.2 min and 18.6 min respectively. The 18.2 min 
peak  corresponded  to  BrtDMB-c(RGDyK)  with  the 
Br-76 on tyrosine, whereas the 18.6 min peak corre-
sponded to BrDMB-c(RDGyK) with the Br-76 on di-
methoxybenzoyl moiety with the peak ratio of 1 to 9.  
The peak assignments were based on the HPLC 
retention  time  of  cold  standards.  When  labeling 
pre-conjugated dimeric DMB-E[c(RGDyK)]2, two ra-
dioactive peaks were also formed with the peak ratio 
of 1 to 3, since there were two tyrosine residues to 
compete with one dimethoxybenzoyl group. Alterna-
tively  the  same  [76Br]BrDMB-E[c(RGDyK)]2  can  be 
prepared  by  coupling  E[c(RGDyK)]2  with 
[76Br]SBDMB  to  give  a  single  radioactive  product. Theranostics 2011, 1 
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[76Br]SBDMB can be easily prepared from SDMB us-
ing peracetic acid without a trialkyltin leaving group. 
The drawback of this procedure is that it requires two 
HPLC  purifications.  When  labeling  pre-conjugated 
DMB-c(RDGfK) and DMB-E[c(RDGfK)]2, only a single 
radioactive product was observed since there were no 
other competing groups present.  
The  cell  binding  results  with  compound  con-
taining  non-radioactive  bromine  demonstrated  that 
the preconjugation had little effect on RGD peptide 
binding affinity with αvβ3 integrin receptor. In the cell 
binding assay, we also included FPPRGD2, which is a 
fluorine-labeled  dimeric  RGD  peptide  recently  de-
veloped in our lab that has higher receptor binding 
affinity and enhanced tumor uptake than monomeric 
RGD  peptide  counterparts.[34-36]  Brominated  RGD 
dimers  showed  cell  binding  affinity  comparable  to 
FPPRGD2.  
In  order  to  further  evaluate  the  pharmacody-
namics  and  pharmacokinetics  of  76Br  labeled  RGD 
compounds, we performed in vivo PET imaging and 
biodistribution  studies  with  two  dimeric  RGD  pep-
tides,  since  the  dimers  have  been  shown  to  have 
higher  binding  affinities  for  αvβ3  integrin  receptor 
than the monomeric analogs. For direct comparison, 
E[c(RGDyK)]2 and pre-conjugated E[c(RGDyK)]2 were 
chosen. Both [76Br]Br-E[c(RGDyK)]2 and [76Br]BrDMB- 
E[c(RGDyK)]2 were prepared using the direct labeling 
method. 76Br was attached on the tyrosine residue in 
[76Br]Br-E[c(RGDyK)]2.  In  [76Br]BrDMB-E[c(RGDyK 
)]2, 76Br was labeled on the dimethoxybenzoyl group. 
Both tracers showed rapid and high tumor accumula-
tion in U87MG xenografted mice. There was no sig-
nificant difference between [76Br]Br-E[c(RGDyK)]2 and 
[76Br]BrDMB-E[c(RGDyK)]2 as to tumor uptake (p > 
0.1)  at  all  time  points  examined.  In  addition,  both 
tracers  showed  similar  excretion  patterns  through 
renal-urinary routes. The integrin αvβ3 binding speci-
ficity  of  [76Br]BrDMB-E[c(RGDyK)]2  was  also  con-
firmed by effective blocking of tumor accumulation 
with excess amounts of unlabeled dimeric RGD pep-
tide. 
Bromination using  N-succinimidyl-2, 6-dimeth-
oxybenzoate  as  a  preconjugated  group  has  several 
advantages over direct labeling on tyrosine residues. 
First, this method can be used to label most proteins 
or peptides that have available ε- or α- amine groups. 
Second, the labeling reaction occurs under mild con-
ditions to help preserve the biological activity of pro-
tein  molecules.  Finally,  bromine  on  the  dimethox-
ybenzoyl  group  may  be  more  resistant  to  potential 
enzymatic  dehalogenation  [37]  after  administration. 
Such dehalogenation could lead to loss of some of the 
radioactivity  from  a  protein  or  peptide  before  it 
reaches its target region and, concurrently, contribute 
to background radioactivity. 
CONCLUSION 
The  newly  developed  N-succinimidyl-2, 
6-dimethoxybenzoate can be used either for one-step 
labeling through pre-conjugation or as the precursor 
for Br-76 labeled prosthetic group for indirect label-
ing. High labeling yields were achieved under mild 
reaction conditions without the need of a trialkyltin 
leaving-group.  Suitably  brominated  RGD  peptides 
showed integrin-specific tumor uptake. The methods 
presented here for RGD peptide labeling can also be 
applied  to  radiobromination  of  other  bioactive  pro-
teins and peptides. 
SUPPLEMENTARY MATERIAL 
Table S1. The optimized Cartesian coordinates of sta-
tionary points for the reaction 1 + CH3COOBr with the 
SCRF-B3LYP/6-31G* method in water with the Gaussian 
09 program package.  
Table S2. Frequencies of stationary points for the reac-
tions of 1 + CH3COOBr with the SCRF-B3LYP/6-31G* 
method in water with the Gaussian 09 program package. 
Table S3. The total energies of reactants, products, and 
transition states of the reaction 1 + CH3COOBr with the 
SCRF-B3LYP/6-31G* method in water with the Gaussian 
09 program package.  
Table S4. The relative energies of reactants, products, 
and transition states of the reaction 1 + CH3COOBr 
with the SCRF-B3LYP/6-31G* method in water with the 
Gaussian 09 program package.  
http://www.thno.org/v01p0341s1.pdf 
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